Kristen Stansbury
Family · Dallas, TXNPI 1508418427
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 194 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 11.5% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 194 payments — averaging $21.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$482
- Novo Nordisk$462
- Mannkind Corporation$395
- AstraZeneca$297
- Sanofi-aventis U.S. LLC$250
- Tandem Diabetes Care, Inc.$213
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,197100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 33 | $482 |
| Novo Nordisk | 19 | $462 |
| Mannkind Corporation | 15 | $395 |
| AstraZeneca | 12 | $297 |
| Sanofi-aventis U.S. LLC | 10 | $250 |
| Tandem Diabetes Care, Inc. | 7 | $213 |
| Xeris Pharmaceuticals, Inc. | 9 | $195 |
| Medtronic | 10 | $178 |
| Insulet Corporation | 9 | $166 |
| Radius Health, Inc. | 7 | $164 |
| Amgen | 9 | $160 |
| Cequr Corporation | 4 | $159 |
| Boehringer Ingelheim | 6 | $136 |
| Dexcom, Inc. | 6 | $132 |
| Corcept Therapeutics | 4 | $88 |
| BETA Bionics, Inc. | 3 | $85 |
| Neurocrine Biosciences, Inc. | 2 | $66 |
| AbbVie | 3 | $62 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $56 |
| Amryt Pharma Holdings Ltd | 3 | $54 |
| Sequel Med Tech, LLC | 2 | $50 |
| IBSA Pharma Inc. | 3 | $48 |
| Kyowa Kirin, Inc. | 2 | $43 |
| Alvogen Inc | 2 | $42 |
| Ultragenyx Pharmaceutical Inc. | 2 | $37 |
| Avvisto Therapeutics, LLC | 2 | $36 |
| Madrigal Pharmaceuticals | 1 | $34 |
| Ascensia Diabetes Care US Inc. | 1 | $24 |
| Zealand Pharma US, Inc. | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Nevro Corp. | 1 | $15 |
| Tolmar, Inc. | 1 | $15 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,197 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 218 | $394,132 |
| MounjaroTirzepatide | 203 | $293,655 |
| FarxigaDapagliflozin Propanediol | 87 | $111,540 |
| JardianceEmpagliflozin | 73 | $107,736 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 27 | $47,515 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $44,519 |
| TrulicityDulaglutide | 41 | $44,439 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $36,945 |
| Tresiba Flextouch U-100Insulin Degludec | 42 | $33,852 |
| Humalog Kwikpen U-100Insulin Lispro | 64 | $28,205 |
| RybelsusSemaglutide | 16 | $27,461 |
| ProliaDenosumab | 12 | $21,087 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 44 | $18,497 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $13,865 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 97 | $13,850 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $462 | $421,593234 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $482 | $341,227256 claims |
| AstraZenecaFarxiga | $297 | $111,54087 claims |
| Boehringer IngelheimJardiance | $136 | $107,73673 claims |
| AmgenProlia | $160 | $21,08712 claims |
| AbbVieSynthroid | $62 | $4,43639 claims |
| Sanofi-aventis U.S. LLCLantus | $250 | $3,27616 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $18 | $1,504115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Dallas
- David WeirDallas$959K
- Sie ThomasDallas$197K
- Marcia HarrisDallas$156K
- Miles HortonDallas$72K
- Natasha SimmonsDallas$38K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.